Literature DB >> 4353775

Maturation of responsiveness to cardioactive drugs. Differential effects of acetylcholine, norepinephrine, theophylline, tyramine, glucagon, and dibutyryl cyclic AMP on atrial rate in hearts of fetal mice.

K Wildenthal.   

Abstract

Freshly isolated hearts of fetal mice of gestational ages ranging between 12 and 22 days (term) were exposed to several concentrations of a variety of chronotropic agents. Acetylcholine (10(-4)-10(-2) M) caused marked bradycardia in all hearts, even after only 12-14 days' gestation (i.e., even before cardiac innervation had occurred), and the intensity of the response increased steadily with advancing age throughout gestation. Responsiveness to norepinephrine was present but minimal at 12-14 days, so that mean atrial rate rose by < 10% with a maximal concentration of the drug (10(-5) M); responsiveness became more marked by 15-16 days (just after the time atrial innervation is thought to begin) and still greater effects appeared just before term. Glucagon had no effect in hearts of < 17 days' gestational age, but caused tachycardia thereafter, indicating that cardiac responsiveness to glucagon differentiates later than does responsiveness to norepinephrine. Responses to theophyl-line in 12-14 day hearts exceeded those to norepinephrine, indicating that the drug can affect heart rate independently of its ability to cause release of endogenous catecholamines. In contrast, tyramine caused no response until 21-22 days, well after the time the beta-receptor has differentiated and after innervation is fairly well developed, suggesting that the drug's primary sympathomimetic effect is indirect rather than direct. Dibutyryl cyclic AMP did not cause tachycardia at any fetal age. It is concluded that maturation of responsiveness of the mouse heart to cardioactive drugs develops in specific patterns for different agents. The identification of differential patterns of maturation for various drugs may provide valuable means for characterizing the differentiation of specific receptors and for investigating possible mechanisms of action of the drugs.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4353775      PMCID: PMC333027          DOI: 10.1172/JCI107411

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  EFFECT OF ISCHEMIA ON KNOWN SUBSTRATES AND COFACTORS OF THE GLYCOLYTIC PATHWAY IN BRAIN.

Authors:  O H LOWRY; J V PASSONNEAU; F X HASSELBERGER; D W SCHULZ
Journal:  J Biol Chem       Date:  1964-01       Impact factor: 5.157

2.  Release of serotonin and catecholamines by drugs.

Authors:  P A SHORE
Journal:  Pharmacol Rev       Date:  1962-12       Impact factor: 25.468

3.  Some effects of adrenaline, noradrenaline and acetylcholine on the foetal circulation in the lamb.

Authors:  G S DAWES; J C MOTT; B R RENNICK
Journal:  J Physiol       Date:  1956-10-29       Impact factor: 5.182

4.  Ontogenesis of the adrenergic nervous system: functional and pharmacologic implications.

Authors:  B L Mirkin
Journal:  Fed Proc       Date:  1972 Jan-Feb

5.  Activation of phosphorylase by cyclic AMP without augmentation of contractility in perfused guinea pig heart.

Authors:  J K Kjekshus; P D Henry; B E Sobel
Journal:  Circ Res       Date:  1971-11       Impact factor: 17.367

6.  Cardiostimulatory effects of cyclic 3',5'-adenosine monophosphate and its acylated derivatives.

Authors:  W R Kukovetz; G Pöch
Journal:  Naunyn Schmiedebergs Arch Pharmakol       Date:  1970

7.  Positive inotropic effects of dibutyryl cyclic adenosine 3',5'-monophosphate.

Authors:  C L Skelton; G S Levey; S E Epstein
Journal:  Circ Res       Date:  1970-01       Impact factor: 17.367

8.  The intrinsic physiologic properties of the developing heart.

Authors:  W F Friedman
Journal:  Prog Cardiovasc Dis       Date:  1972 Jul-Aug       Impact factor: 8.194

9.  Sensitivity changes in the dog heart to norepinephrine, calcium and aminophyline resulting from pretreatment with reserpine.

Authors:  D P Westfall; W W Fleming
Journal:  J Pharmacol Exp Ther       Date:  1968-01       Impact factor: 4.030

10.  Responses to cardioactive drugs of fetal mouse hearts maintained in organ culture.

Authors:  K Wildenthal
Journal:  Am J Physiol       Date:  1971-07
View more
  7 in total

1.  Fetal mouse hearts: a model for studying ischemia.

Authors:  J S Ingwall; M DeLuca; H D Sybers; K Wildenthal
Journal:  Proc Natl Acad Sci U S A       Date:  1975-07       Impact factor: 11.205

2.  Age-related regulation of excitation-contraction coupling in rat heart.

Authors:  Hilmi B Kandilci; Erkan Tuncay; Esma N Zeydanli; Nazli N Sozmen; Belma Turan
Journal:  J Physiol Biochem       Date:  2011-02-02       Impact factor: 4.158

3.  Emergence of beta-adrenergic sensitivity in the developing chicken heart.

Authors:  S Lipshultz; J Shanfeld; S Chacko
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

4.  Responsiveness to glucagon in fetal hearts. Species variability and apparent disparities between changes in beating, adenylate cyclase activation, and cyclic AMP concentration.

Authors:  K Wildenthal; D O Allen; J Karlsson; J R Wakeland; C M Clark
Journal:  J Clin Invest       Date:  1976-03       Impact factor: 14.808

5.  Rate, force and cyclic adenosine 3',5'-monophosphate responses to (--)-adrenaline in neonatal rat heart tissue.

Authors:  T L Au; G A Collins; M J Walker
Journal:  Br J Pharmacol       Date:  1980-08       Impact factor: 8.739

6.  The postnatal development of adrenoceptor responses to agonists and electrical stimulation in rat isolated atria.

Authors:  N B Standen
Journal:  Br J Pharmacol       Date:  1978-09       Impact factor: 8.739

7.  Physiological and genomic consequences of adrenergic deficiency during embryonic/fetal development in mice: impact on retinoic acid metabolism.

Authors:  Kingsley Osuala; Candice N Baker; Ha-Long Nguyen; Celines Martinez; David Weinshenker; Steven N Ebert
Journal:  Physiol Genomics       Date:  2012-08-21       Impact factor: 3.107

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.